



**P.17019/01/2019-PvPI**  
**Indian Pharmacopoeia Commission**  
**National Coordination Centre-Pharmacovigilance Programme of India**  
**(Ministry of Health & Family Welfare, Govt. of India)**

**Sector-23, Rajnagar,**  
**Ghaziabad-201002, U.P**  
**Dated: February 14, 2019**

**Drugs Safety Alert**

The preliminary analysis of Adverse Drugs Reactions from the PvPI database reveals that the following drug is associated with the risk as given below.

**Table**

<b>Sl. No</b>	<b>Suspected Drugs</b>	<b>Indication</b>	<b>Adverse Drugs Reactions</b>
1	Levetiracetam	Anti-epileptic, i) As monotherapy in partial onset seizures with or without secondary generalisation in patients with 16 years of age with newly diagnosed epilepsy. (ii) As adjunctive therapy in myoclonic seizures in adults and adolescents from 12 years of age with Juvenile.	Anencephaly
2	Cetirizine	For the treatment of seasonal/perennial allergic rhinitis & chronic idiopathic urticaria in infants & children.	Tachycardia

Health care professionals, Patients/Consumers are advised to closely monitor the possibility of the above ADRs associated with the use of above drugs. If such reactions are encountered, please report to the NCC-PvPI either by filling of Suspected Adverse Drug Reactions Reporting Form/Medicines Side Effect Reporting Form for Consumer (<http://www.ipc.gov.in>) or by PvPI Helpline No. 1800-180-3024.